JPS6242887B2 - - Google Patents
Info
- Publication number
- JPS6242887B2 JPS6242887B2 JP52009594A JP959477A JPS6242887B2 JP S6242887 B2 JPS6242887 B2 JP S6242887B2 JP 52009594 A JP52009594 A JP 52009594A JP 959477 A JP959477 A JP 959477A JP S6242887 B2 JPS6242887 B2 JP S6242887B2
- Authority
- JP
- Japan
- Prior art keywords
- polyethylene glycol
- fibrinogen
- factor
- precipitate
- ahf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 45
- 102000008946 Fibrinogen Human genes 0.000 claims description 30
- 108010049003 Fibrinogen Proteins 0.000 claims description 30
- 239000002202 Polyethylene glycol Substances 0.000 claims description 30
- 229940012952 fibrinogen Drugs 0.000 claims description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 30
- 239000002244 precipitate Substances 0.000 claims description 28
- 238000001556 precipitation Methods 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 17
- 239000012141 concentrate Substances 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 6
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000000047 product Substances 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000001698 pyrogenic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 238000001226 reprecipitation Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- YBHYYFYQHRADCQ-UHFFFAOYSA-N 2-aminoacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O YBHYYFYQHRADCQ-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000798165 Homo sapiens Trichohyalin Proteins 0.000 description 1
- 206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000047998 human TCHH Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processing Of Solid Wastes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/653,973 US4069216A (en) | 1975-06-16 | 1976-01-30 | Simplified methods for preparation of very high purity Factor VIII concentrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52102410A JPS52102410A (en) | 1977-08-27 |
| JPS6242887B2 true JPS6242887B2 (fi) | 1987-09-10 |
Family
ID=24623016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP959477A Granted JPS52102410A (en) | 1976-01-30 | 1977-01-31 | Easy method of production of highly purified concentrated factorr8 |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS52102410A (fi) |
| AR (1) | AR214625A1 (fi) |
| AT (1) | AT354632B (fi) |
| BE (1) | BE850852A (fi) |
| BR (1) | BR7700554A (fi) |
| CA (1) | CA1101332A (fi) |
| DE (1) | DE2703620C2 (fi) |
| DK (1) | DK146855C (fi) |
| ES (1) | ES455473A1 (fi) |
| FR (1) | FR2339621A1 (fi) |
| GB (1) | GB1557609A (fi) |
| LU (1) | LU76652A1 (fi) |
| MX (1) | MX5197E (fi) |
| NL (1) | NL179290C (fi) |
| NO (1) | NO145563C (fi) |
| SE (1) | SE442953B (fi) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084198B2 (en) | 2012-06-26 | 2021-08-10 | Conwed Plastics Llc | Membrane filtration using low energy feed spacer |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| AT369263B (de) * | 1980-08-27 | 1982-12-27 | Immuno Ag | Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates |
| EP0062456B1 (en) * | 1981-04-08 | 1988-12-21 | United Kingdom Atomic Energy Authority | Blood fractionation improvement |
| US4382028A (en) * | 1982-07-19 | 1983-05-03 | Monsanto Company | Separation of plasma proteins from cell culture systems |
| FR2535173A1 (fr) * | 1982-11-03 | 1984-05-04 | Protein Sa | Produits obtenus a partir de sang d'animaux d'abattoirs et leur procede d'obtention |
| FR2603805A1 (fr) * | 1986-09-16 | 1988-03-18 | Transfusion Sanguine Assoc Rgl | Procede d'inactivation par ozonolyse de micro-organismes contaminants presents dans des materiaux biologiques essentiellement proteiques, les produits obtenus et leurs applications biologiques et analytiques |
| HRP940645A2 (en) * | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (fi) * | 1962-01-03 | |||
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| US3770631A (en) * | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
| US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
| US4073886A (en) * | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
| US3893990A (en) * | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
-
1977
- 1977-01-26 CA CA270,497A patent/CA1101332A/fr not_active Expired
- 1977-01-27 SE SE7700864A patent/SE442953B/xx not_active IP Right Cessation
- 1977-01-28 AR AR266368A patent/AR214625A1/es active
- 1977-01-28 DK DK36477A patent/DK146855C/da not_active IP Right Cessation
- 1977-01-28 FR FR7702396A patent/FR2339621A1/fr active Granted
- 1977-01-28 DE DE2703620A patent/DE2703620C2/de not_active Expired
- 1977-01-28 NO NO770293A patent/NO145563C/no unknown
- 1977-01-28 GB GB3643/77A patent/GB1557609A/en not_active Expired
- 1977-01-28 AT AT53277A patent/AT354632B/de not_active IP Right Cessation
- 1977-01-28 MX MX775394U patent/MX5197E/es unknown
- 1977-01-28 BE BE174461A patent/BE850852A/xx not_active IP Right Cessation
- 1977-01-28 NL NLAANVRAGE7700927,A patent/NL179290C/xx not_active IP Right Cessation
- 1977-01-28 BR BR7700554A patent/BR7700554A/pt unknown
- 1977-01-28 LU LU76652A patent/LU76652A1/xx unknown
- 1977-01-29 ES ES455473A patent/ES455473A1/es not_active Expired
- 1977-01-31 JP JP959477A patent/JPS52102410A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084198B2 (en) | 2012-06-26 | 2021-08-10 | Conwed Plastics Llc | Membrane filtration using low energy feed spacer |
Also Published As
| Publication number | Publication date |
|---|---|
| DK146855C (da) | 1984-07-02 |
| AT354632B (de) | 1979-01-25 |
| DK36477A (da) | 1977-07-31 |
| LU76652A1 (fi) | 1978-09-13 |
| ES455473A1 (es) | 1978-01-01 |
| FR2339621A1 (fr) | 1977-08-26 |
| NL179290B (nl) | 1986-03-17 |
| SE442953B (sv) | 1986-02-10 |
| MX5197E (es) | 1983-04-25 |
| DK146855B (da) | 1984-01-23 |
| NL7700927A (nl) | 1977-08-02 |
| NO145563B (no) | 1982-01-11 |
| DE2703620A1 (de) | 1977-08-04 |
| JPS52102410A (en) | 1977-08-27 |
| GB1557609A (en) | 1979-12-12 |
| BE850852A (fr) | 1977-07-28 |
| NO145563C (no) | 1982-04-21 |
| AR214625A1 (es) | 1979-07-13 |
| CA1101332A (fr) | 1981-05-19 |
| FR2339621B1 (fi) | 1980-06-06 |
| DE2703620C2 (de) | 1984-11-22 |
| SE7700864L (sv) | 1977-07-31 |
| ATA53277A (de) | 1979-06-15 |
| NL179290C (nl) | 1986-08-18 |
| NO770293L (no) | 1977-08-02 |
| BR7700554A (pt) | 1977-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4069216A (en) | Simplified methods for preparation of very high purity Factor VIII concentrate | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| US4203891A (en) | Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| US8003706B2 (en) | Enhanced production of blood clotting factors and fibrin fabric | |
| US7879332B2 (en) | Ultra-high yield intravenous immune globulin preparation | |
| US4386068A (en) | Antihemophilic factor concentrate and method for preparation | |
| JPH0676337B2 (ja) | 高純度抗血友病性因子濃縮物の製造法 | |
| JPH0348888B2 (fi) | ||
| JPS5928537B2 (ja) | フアクタ−８高濃縮物の製造方法 | |
| JPS5910645B2 (ja) | 第８因子の濃縮・精製方法 | |
| US4739039A (en) | Method for preparing antihemophilic factor (AHF) by cold precipitation and for improving solubility of recovered AHF product | |
| JPS6242887B2 (fi) | ||
| US4285933A (en) | Process for concentrating blood coagulation Factor XIII derived from human placentae | |
| JPH0381290A (ja) | 精製されたアルブミン溶液の製造方法 | |
| US4057628A (en) | Removal of hepatitis associated antigen from plasma | |
| JPS61189228A (ja) | 血液凝固第８因子製剤の製法 | |
| US4478825A (en) | Warm ethanol method for preparation of low fibrinogen antihemophilic factor | |
| IL44881A (en) | Preparation of a blood fraction rich in albumin and alpha and beta-globulins | |
| JP2931319B2 (ja) | 血液凝固第▲ｖｉｉｉ▼因子の製造法 | |
| JPS62195331A (ja) | 血液凝固第８因子製剤の製法 | |
| US3038838A (en) | Method of producing purified properdin | |
| WO2023215722A1 (en) | Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration | |
| NO149610B (no) | Fremgangsmaate for rensing av den antihemofile faktor, faktor viii |